B. Increased platelet cyclic AMP due to reduced Gi-mediated inhibition of adenylate cyclase
Why this is correct
The platelet P2Y12 receptor binds ADP and signals through Gi, suppressing adenylate cyclase and lowering cAMP, which facilitates platelet activation and sustained glycoprotein IIb/IIIa activation. Clopidogrel irreversibly antagonizes P2Y12 after hepatic bioactivation. Blocking this Gi input permits higher cAMP, reducing ADP-driven platelet aggregation. This differs from aspirin, which inhibits COX-1 and thromboxane A2 generation.
Why each option is correct or incorrect
P2Y12 activation normally decreases cAMP; receptor blockade tends to prevent that decrease.
Correct: reducing Gi inhibition of adenylate cyclase raises cAMP and suppresses platelet activation.
PAR1 is a thrombin receptor, not the target of clopidogrel.
COX-1 inhibition characterizes aspirin rather than a P2Y12 antagonist.
High-yield notes
- P2Y12 receptor couples to Gi.
- P2Y12 blockade reduces ADP-dependent platelet aggregation.
- Clopidogrel is a prodrug requiring metabolic activation.
Clopidogrel inhibits P2Y12; aspirin inhibits COX-1.
Do not confuse P2Y12's Gi pathway with P2Y1's Gq-mediated calcium signal.